Oncolys BioPharma Inc.JP:4588
| Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 |
|---|
| Profit (loss) before income taxes | -101 | -633 | -737 | -855 | -928 | -1,087 | -1,230 | -909 | -2,091 | -1,612 | -1,146 | -1,936 |
|---|
| Depreciation | 17 | 17 | 13 | 17 | 15 | 1 | 2 | 3 | 5 | 6 | 1 | 2 |
|---|
| Impairment losses | - | 8 | - | - | 58 | - | - | - | 11 | 20 | 4 | 22 |
|---|
| Amortization of restricted stock remuneration | - | - | - | - | - | - | - | - | 14 | 69 | 18 | 1 |
|---|
| Gain on transfer of receivables | - | - | - | - | - | - | - | - | - | - | -21 | - |
|---|
| Share-based payment expenses | - | - | - | - | - | - | - | 126 | 377 | 209 | 58 | 9 |
|---|
| Increase (decrease) in provision for retirement benefits | 0 | 1 | 1 | -0 | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 0 |
|---|
| Interest and dividend income | -6 | -1 | -3 | -4 | -5 | -4 | -21 | -20 | -1 | -0 | -1 | -1 |
|---|
| Interest expenses | 8 | 3 | 5 | 4 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 |
|---|
| Issuance cost of share acquisition rights-OpeCF | - | - | - | - | - | - | - | - | - | - | - | 3 |
|---|
| Share issuance costs | 1 | 40 | 0 | - | - | - | - | - | - | - | 0 | 9 |
|---|
| Foreign exchange losses (gains) | -31 | -43 | -1 | 1 | 1 | 8 | 6 | 1 | 17 | -42 | -73 | -24 |
|---|
| Decrease (increase) in trade receivables | - | -1 | -6 | 5 | -65 | -22 | 39 | -119 | 99 | -282 | 352 | - |
|---|
| Decrease (increase) in inventories | 1 | -4 | 3 | 3 | 1 | -3 | 8 | -4 | 4 | -1 | -13 | 19 |
|---|
| Decrease (increase) in prepaid expenses | - | - | - | - | - | - | 22 | 56 | -4 | -33 | 14 | 4 |
|---|
| Decrease (increase) in accounts receivable - other | -2 | 1 | -23 | 24 | 0 | -0 | -0 | 0 | -1 | -3 | -198 | 123 |
|---|
| Decrease (increase) in consumption taxes refund receivable | - | - | - | - | - | - | - | - | -95 | 75 | -56 | 28 |
|---|
| Decrease (increase) in advance payment | - | -10 | -57 | 58 | -43 | 40 | 9 | -44 | 4 | -191 | -272 | 224 |
|---|
| Increase (decrease) in accounts payable - other | -38 | 12 | 17 | 3 | 46 | -1 | -18 | 182 | -61 | -100 | -45 | 133 |
|---|
| Increase (decrease) in contract liabilities | - | - | - | - | - | - | - | - | - | - | -286 | - |
|---|
| Other, net | 7 | 16 | -20 | -10 | 10 | -26 | 22 | 45 | -7 | 53 | -55 | 21 |
|---|
| Subtotal | -153 | -594 | -809 | -752 | -900 | -1,091 | -1,182 | -232 | -1,458 | -1,734 | -1,712 | -1,359 |
|---|
| Interest and dividends received | 6 | 1 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
|---|
| Interest paid | -8 | -3 | -5 | -4 | -3 | -3 | -3 | -4 | -4 | -4 | -4 | -4 |
|---|
| Income taxes refund (paid) | - | - | - | - | - | - | - | - | - | - | -1 | 25 |
|---|
| Net cash provided by (used in) operating activities | -151 | -599 | -814 | -756 | -903 | -1,097 | -1,188 | -238 | -1,465 | -1,742 | -1,717 | -1,337 |
|---|
| Payments into time deposits | -417 | -75 | -3,545 | -0 | -0 | -400 | -0 | -0 | -0 | -0 | -0 | -0 |
|---|
| Gain on sales of receivables | - | - | - | - | - | - | - | - | - | - | 21 | - |
|---|
| Purchase of property, plant and equipment | -15 | -1 | -23 | - | -21 | -1 | -2 | -3 | -3 | -1 | -1 | -6 |
|---|
| Proceeds from sale of property, plant and equipment | 0 | - | 10 | - | 1 | - | - | - | - | - | - | 0 |
|---|
| Proceeds from refund of leasehold and guarantee deposits | 1 | - | 9 | 6 | 1 | 1 | - | - | - | 0 | 0 | 0 |
|---|
| Net cash provided by (used in) investing activities | -271 | 110 | -3,409 | 1,755 | 257 | 132 | 342 | -4 | -38 | -1 | 20 | -5 |
|---|
| Net increase (decrease) in short-term borrowings | -19 | 78 | 7 | -80 | - | - | - | - | - | - | -100 | - |
|---|
| Proceeds from long-term borrowings | 130 | 165 | 35 | - | - | 100 | - | 200 | 100 | 100 | 100 | 100 |
|---|
| Repayments of long-term borrowings | -2 | -28 | -30 | -33 | -33 | -25 | -33 | -78 | -100 | -122 | -111 | -194 |
|---|
| Repayments of lease liabilities | -2 | -2 | -7 | -10 | -11 | -11 | -10 | -6 | -3 | -3 | -3 | -5 |
|---|
| Proceeds from issuance of shares | 256 | 5,233 | 6 | 0 | 37 | 1,409 | 1,188 | 1,007 | 246 | 3,085 | - | 1,223 |
|---|
| Proceeds from issuance of share acquisition rights | - | - | 4 | 3 | 13 | 3 | 12 | - | - | 43 | - | 18 |
|---|
| Purchase of treasury shares | - | - | - | - | - | - | - | - | -0 | -0 | -0 | - |
|---|
| Other payments | - | - | - | - | - | - | - | - | - | -12 | -0 | - |
|---|
| Net cash provided by (used in) financing activities | 362 | 5,440 | -0 | -120 | 6 | 1,477 | 1,147 | 1,123 | 242 | 3,091 | -114 | 1,143 |
|---|
| Effect of exchange rate change on cash and cash equivalents | 1 | 29 | 1 | -1 | -1 | -8 | -6 | -1 | -14 | 38 | 67 | 21 |
|---|
| Net increase (decrease) in cash and cash equivalents | -59 | 4,981 | -4,222 | 878 | -641 | 503 | 296 | 879 | -1,275 | 1,387 | -1,743 | -178 |
|---|